Neimeth International Pharmaceuticals Plc (NGX: NEIMETH)

NEIMETH Statistics

Total Valuation

Neimeth International Pharmaceuticals has a market cap or net worth of NGN 8.46 billion. The enterprise value is 10.66 billion.

Market Cap	8.46B
Enterprise Value	10.66B

Important Dates

The next estimated earnings date is Tuesday, October 29, 2024.

Earnings Date	Oct 29, 2024
Ex-Dividend Date	n/a

Share Statistics

Neimeth International Pharmaceuticals has 4.27 billion shares outstanding. The number of shares has increased by 38.46% in one year.

Shares Outstanding	4.27B
Shares Change (YoY)	+38.46%
Shares Change (QoQ)	+3.51%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.91
PB Ratio	5.07
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 49.47, with an EV/FCF ratio of -8.61.

EV / Earnings	-4.81
EV / Sales	3.67
EV / EBITDA	49.47
EV / EBIT	145.83
EV / FCF	-8.61

Financial Position

The company has a current ratio of 0.76, with a Debt / Equity ratio of 2.52.

Current Ratio	0.76
Quick Ratio	0.39
Debt / Equity	2.52
Debt / EBITDA	19.52
Debt / FCF	-3.40
Interest Coverage	0.09

Financial Efficiency

Return on equity (ROE) is -79.67% and return on invested capital (ROIC) is 0.69%.

Return on Equity (ROE)	-79.67%
Return on Assets (ROA)	0.48%
Return on Capital (ROIC)	0.69%
Revenue Per Employee	14.40M
Profits Per Employee	-10.96M
Employee Count	202
Asset Turnover	0.31
Inventory Turnover	0.70

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +20.00% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+20.00%
50-Day Moving Average	1.99
200-Day Moving Average	1.85
Relative Strength Index (RSI)	50.35
Average Volume (20 Days)	1,238,048

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Neimeth International Pharmaceuticals had revenue of NGN 2.91 billion and -2.21 billion in losses. Loss per share was -0.52.

Revenue	2.91B
Gross Profit	1.34B
Operating Income	73.11M
Pretax Income	-2.11B
Net Income	-2.21B
EBITDA	215.51M
EBIT	73.11M
Loss Per Share	-0.52

Balance Sheet

The company has 2.00 billion in cash and 4.21 billion in debt, giving a net cash position of -2.20 billion or -0.52 per share.

Cash & Cash Equivalents	2.00B
Total Debt	4.21B
Net Cash	-2.20B
Net Cash Per Share	-0.52
Equity (Book Value)	1.67B
Book Value Per Share	0.39
Working Capital	-1.74B

Cash Flow

In the last 12 months, operating cash flow was -173.60 million and capital expenditures -1.07 billion, giving a free cash flow of -1.24 billion.

Operating Cash Flow	-173.60M
Capital Expenditures	-1.07B
Free Cash Flow	-1.24B
FCF Per Share	-0.29

Margins

Gross margin is 46.12%, with operating and profit margins of 2.51% and -76.13%.

Gross Margin	46.12%
Operating Margin	2.51%
Pretax Margin	-72.42%
Profit Margin	-76.13%
EBITDA Margin	7.41%
EBIT Margin	2.51%
FCF Margin	-42.58%

Dividends & Yields

Neimeth International Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-38.46%
Shareholder Yield	-38.46%
Earnings Yield	-26.17%
FCF Yield	-14.64%

Stock Splits

The last stock split was on January 18, 2019. It was a forward split with a ratio of 1.1.

Last Split Date	Jan 18, 2019
Split Type	Forward
Split Ratio	1.1

Scores

Neimeth International Pharmaceuticals has an Altman Z-Score of 0.27. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.27
Piotroski F-Score	n/a